Comparison of Awakening Versus Bedtime Dosing of Ramipril in Subjects With Essential Hypertension

Summary

This prospective chronotherapy trial will investigate the potential differing efficacy of ramipril in doses from 5 to 10 mg/day when administered, as a monotherapy either upon awakening from nighttime sleep or at bedtime, to diurnally active patients with grade 1 or 2 essential hypertension, who will be evaluated by 48-hour ABPM before and after pharmacologic intervention. The benefits from this trial may be extremely important, taking into account 1. the high prevalence of non-dipping among patients with essential hypertension 2. the need for a proper 24-hour BP control with particular emphasis on the regulation of nighttime resting BP mean 3. the lacking information on the administration-time dependent effects on BP of ramipril, a widely used ACEI in doses of 5-10 mg/day.

Timeline

Start

2007-03

Primary completion

2008-12

Completion

2008-12

Publications

• Results Hermida RC, Ayala DE. Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing. Hypertension. 2009 Jul;54(1):40-6. doi: 10.1161/HYPERTENSIONAHA.109.130203. Epub 2009 May 11.

Drugs

Indications